Scientists find intra cellular pathway driving a deadly sub-type of breast cancer



Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer. Studies suggest that the PD-1 signaling pathway may play an important role in tumor evasion and escape from host immune responses and may

Full Post: Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

An intra cellular pathway not previously linked to breast cancer is driving a sub-type of the disease that is highly lethal and disproportionately over-represented in African American women.

The pathway regulates how cells identify and destroy proteins and represents a class of genes called proteasome targeting complexes. The work shows that basal cancer cells degrade the tumor suppressor gene p27 by making a new type of proteasome targeting complex. The gene p27 is one of a handful of proteins that are expressed in normal cells and act to prevent rapid cell growth, which is indicative of cancer. Beyond chemotherapy, no specific therapeutic target has been identified for this sub-type of cancer, found in between 12 to 15 percent of breast cancers in the general population and up to 25 percent of cases in African American women.

“The mortality rates in this subgroup of cancer are very high,” said Tim Lane, senior author of the paper and a researcher at UCLA’s Jonsson Comprehensive Cancer Center. “The possibility that this new proteasome targeting complex might provide targets for therapeutic intervention is a completely new area for breast cancer research.”

The research, done in animal models and human breast cancer cell lines, is published in the Nov. 15 issue of the journal Genes and Development .

Scientists have identified five to seven different sub-types of breast cancer. Basal-like breast cancers currently are among the most difficult to treat.

Targeted therapeutics are available for several sub-types. Women with HER-2 positive breast cancers can receive Herceptin, which when paired with chemotherapy extends disease-free survival by more than 50 percent. HER-2 positive women used to have the worst prognoses before Herceptin was developed. They now have the best prognoses because the drug targets what’s broken in the cancer cell that is driving the disease. Another sub-type includes women with Estrogen Receptor positive cancers. These patients have several drugs available, such as Tamoxifen, that suppress the actions of estrogen on breast cancer tissue and thus control the disease.

Next up, Lane and his team plan to use protein chemistry and genetic tools to uncover the molecular components that participate in this new proteasome targeting complex, which could identify alterations - like HER-2 - that can be targeted in cancer cells and leave the healthy cells alone. That would give patients with this aggressive cancer sub-type a more effective and less toxic option than chemotherapy.

“This research has the potential to identify clinically relevant markers of a large subgroup of human breast cancer and find a novel therapeutic target that could be exploited with appropriate pharmaceutical agents,” said Lane, who is an associate professor of obstetrics and gynecology. “We need a new paradigm to think about how to treat these cancers.”

Lane’s research also showed that basal-like breast cancer cells are most like breast stem cells, which generate the tissues of the breast. One way they’re alike is that they are resistant to chemotherapy and do not express mature breast markers like estrogen receptor. These features make basal-like breast cancers so difficult to treat.

Another mystery Lane and his team hope to focus on is why basal-like breast cancers are over-represented in African American women. It could be related to genetic features in the patient, or to other complex factors such as access to effective early intervention, Lane said.

Lane is currently working to validate his work in human disease and identify all the key players in this molecular pathway.

“We’re still missing a couple of the key players. We currently understand the shape and general features of the complex, but hope to find all the components in the next couple of years,” Lane said. “It is a great time to be involved in this research.”

http://www.ucla.edu/

Link




A new study reveals that the metadherin gene (MTDH) plays a role in both cancer metastasis and resistance to chemotherapy. The research, published by Cell Press in the January 6th issue of the journal Cancer Cell , identifies MTDH as a promising therapeutic target for high risk breast cancers. “Most breast cancer patients resist currently

Full Post: Metadherin gene plays dual role in breast cancers with poor prognosis



Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by

Full Post: Lapatinib benefits women with HER2-positive breast cancer



A new technique to study genetic changes that can lead to breast cancer could be one step closer. The University of Nottingham has received £15,000 from the charity Breast Cancer Campaign to fill in one of the research gaps identified by the country’s top breast cancer experts in a recent study carried out by the

Full Post: New technique to study the genetics of breast cancer



Cancer Research UK scientists have found that a test, already used in breast cancer diagnosis, can also predict who will and who won’t benefit from commonly used chemotherapy drugs. The research shows that women who have a duplication of chromosome 17 in their tumour will benefit from anthracycline drugs, while others can be spared the

Full Post: New research moves us one step closer to personalised breast cancer treatment



Canadian researchers have identified a new protein in the progression of breast cancer. According to a recent study from the Université de Montréal and the University of Alberta, published in the Journal of Biological Chemistry, the protein ARF1 plays a critical role in cancer cell growth and the spread of tumours. Targeting this protein with

Full Post: Discovery of new protein that triggers breast cancer